Ashleigh Barreto
Contatto Relazioni con gli Investitori presso VIRACTA THERAPEUTICS, INC.
Profilo
Ashleigh Barreto is currently the Head of Investor Relations and Corporate Communications at Viracta Therapeutics, Inc. Prior to this, she worked as the Director of Communications and Investor Relations at Adamas Pharmaceuticals LLC and as the Head of Investor and Media Relations at XOMA Corp.
Posizioni attive di Ashleigh Barreto
| Società | Posizione | Inizio |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/10/2021 |
Precedenti posizioni note di Ashleigh Barreto
| Società | Posizione | Fine |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | 01/12/2018 |
| XOMA CORPORATION | Contatto Relazioni con gli Investitori | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Borsa valori
- Insiders
- Ashleigh Barreto
